Trial · NCT02914119
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
NCT02914119, Completed, Jakob Louis Thomsen; results first posted 2019-09-12
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals. Trials, record NCT02914119. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02914119
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
- NCT number
- NCT02914119
- Status
- Completed
- Enrollment
- 30,430 participants, actual
- Lead sponsor
- Jakob Louis Thomsen
- Conditions
- Neuromuscular Blockade
- Interventions
- Rocuronium, Succinylcholine, Cisatracurium, Mivacurium, Objective neuromuscular monitoring (acceleromyography), Sugammadex, Neostigmine
- First posted
- 2016-09-26
- Last updated
- 2019-09-12
- Results first posted
- 2019-09-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no) | in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours | |
| Primary | Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no) | in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours | |
| Secondary | Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA | in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours | The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation. |
| Secondary | Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no) | in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours | |
| Secondary | Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no) | in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours | |
| Secondary | Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively | in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes | |
| Secondary | Number of Participants With and Without Mild Oxygen Desaturation (<90%, But >80%) in Cases Receiving a Non-depolarizing NMBA | in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours | |
| Secondary | Number of Participants With and Without Severe Oxygen Desaturation (<80%) in Cases Receiving a Non-depolarizing NMBA | in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no) | in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours | Patients receiving non-depolarizing neuromuscular blocking agent | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no) | in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours | Patients receiving succinylcholine only | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA | in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours | Only participants with data on the outcome was analyzed, as per protocol. | Train-of-four ratio | MEDIAN |
| SECONDARY | Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no) | in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours | Only participants with data on the outcome was analyzed, as per protocol. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no) | in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours | Only participants with data on the outcome was analyzed, as per protocol. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively | in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes | Only participants with data on the outcome was analyzed, as per protocol. | Minutes | MEDIAN |
| SECONDARY | Number of Participants With and Without Mild Oxygen Desaturation (<90%, But >80%) in Cases Receiving a Non-depolarizing NMBA | in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours | Only participants with data on the outcome was analyzed, as per protocol. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With and Without Severe Oxygen Desaturation (<80%) in Cases Receiving a Non-depolarizing NMBA | in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours | Only participants with data on the outcome was analyzed, as per protocol. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no) | Eligible Patients | Monitoring applied | 14463 | Participants | |
| Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no) | Eligible Patients | Monitoring not applied | 2062 | Participants | |
| Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no) | Eligible Patients | Monitoring applied | 4224 | Participants | |
| Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no) | Eligible Patients | Monitoring not applied | 9681 | Participants | |
| Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA | Eligible Patients | 0.97 | Inter-Quartile Range 0.90 to 1.06 | Train-of-four ratio | |
| Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no) | Eligible Patients | Yes | 145 | Participants | |
| Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no) | Eligible Patients | No | 12945 | Participants | |
| Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no) | Eligible Patients | Yes | 8570 | Participants | |
| Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no) | Eligible Patients | No | 7955 | Participants | |
Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively | Eligible Patients | 97 | Inter-Quartile Range 63 to 157 | Minutes |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Eligible Patients | 30,430 | |
| Overall Study | COMPLETED | Eligible Patients | 30,430 | |
| Overall Study | NOT COMPLETED | Eligible Patients | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Eligible Patients | 0 | 0 |
| Total, other adverse events | Eligible Patients | 0 | 0 |
| Total, serious adverse events | Eligible Patients | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02914119
GET https://conductscience.org/api/trials/v1/NCT02914119/registered